Acute treatment of mania

An update on new medications

Prashant Gajwani, David E. Kemp, David J. Muzina, Guohua Xia, Keming Gao, Joseph R. Calabrese

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Acute mania is frequently a medical emergency requiring hospitalization for behavioral control, rapid resolution of irritability, agitation, de-escalation of mood, and decreasing of risk-taking behavior. Lithium efficacy in the management of acute mania was reported in 1949 and approved by the US Food and Drug Administration (FDA) in 1970. Chlorpromazine, from the class of typical antipsychotics, was approved for treatment of bipolar disorder in 1973. Typical antipsychotics were frequently used alone and as adjunct for the treatment of bipolar mania for the next 2 decades. Divalproex was approved by the FDA for the treatment of acute mania in 1994. Since the approval of olanzapine in 2000, all five atypical antipsychotics, namely risperidone (2003), quetiapine (2004), ziprasidone (2004), and aripiprazole (2004), have been approved by the FDA for the management of acute mania. Clozapine is the only atypical antipsychotic not FDA approved for any phase of bipolar disorder. This article will systematically review some of the major studies published, randomized controlled monotherapy, and adjunct therapy trials involving five atypical antipsychotics and newer anticonvulsants for the treatment of acute bipolar mania.

Original languageEnglish (US)
Pages (from-to)504-509
Number of pages6
JournalCurrent Psychiatry Reports
Volume8
Issue number6
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Bipolar Disorder
Antipsychotic Agents
United States Food and Drug Administration
Therapeutics
olanzapine
Risperidone
Clozapine
Chlorpromazine
Valproic Acid
Risk-Taking
Lithium
Anticonvulsants
Hospitalization
Emergencies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Gajwani, P., Kemp, D. E., Muzina, D. J., Xia, G., Gao, K., & Calabrese, J. R. (2006). Acute treatment of mania: An update on new medications. Current Psychiatry Reports, 8(6), 504-509. https://doi.org/10.1007/s11920-006-0058-3

Acute treatment of mania : An update on new medications. / Gajwani, Prashant; Kemp, David E.; Muzina, David J.; Xia, Guohua; Gao, Keming; Calabrese, Joseph R.

In: Current Psychiatry Reports, Vol. 8, No. 6, 12.2006, p. 504-509.

Research output: Contribution to journalArticle

Gajwani, P, Kemp, DE, Muzina, DJ, Xia, G, Gao, K & Calabrese, JR 2006, 'Acute treatment of mania: An update on new medications', Current Psychiatry Reports, vol. 8, no. 6, pp. 504-509. https://doi.org/10.1007/s11920-006-0058-3
Gajwani P, Kemp DE, Muzina DJ, Xia G, Gao K, Calabrese JR. Acute treatment of mania: An update on new medications. Current Psychiatry Reports. 2006 Dec;8(6):504-509. https://doi.org/10.1007/s11920-006-0058-3
Gajwani, Prashant ; Kemp, David E. ; Muzina, David J. ; Xia, Guohua ; Gao, Keming ; Calabrese, Joseph R. / Acute treatment of mania : An update on new medications. In: Current Psychiatry Reports. 2006 ; Vol. 8, No. 6. pp. 504-509.
@article{043260de90514ea085e41437ec5b3646,
title = "Acute treatment of mania: An update on new medications",
abstract = "Acute mania is frequently a medical emergency requiring hospitalization for behavioral control, rapid resolution of irritability, agitation, de-escalation of mood, and decreasing of risk-taking behavior. Lithium efficacy in the management of acute mania was reported in 1949 and approved by the US Food and Drug Administration (FDA) in 1970. Chlorpromazine, from the class of typical antipsychotics, was approved for treatment of bipolar disorder in 1973. Typical antipsychotics were frequently used alone and as adjunct for the treatment of bipolar mania for the next 2 decades. Divalproex was approved by the FDA for the treatment of acute mania in 1994. Since the approval of olanzapine in 2000, all five atypical antipsychotics, namely risperidone (2003), quetiapine (2004), ziprasidone (2004), and aripiprazole (2004), have been approved by the FDA for the management of acute mania. Clozapine is the only atypical antipsychotic not FDA approved for any phase of bipolar disorder. This article will systematically review some of the major studies published, randomized controlled monotherapy, and adjunct therapy trials involving five atypical antipsychotics and newer anticonvulsants for the treatment of acute bipolar mania.",
author = "Prashant Gajwani and Kemp, {David E.} and Muzina, {David J.} and Guohua Xia and Keming Gao and Calabrese, {Joseph R.}",
year = "2006",
month = "12",
doi = "10.1007/s11920-006-0058-3",
language = "English (US)",
volume = "8",
pages = "504--509",
journal = "Current Psychiatry Reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Acute treatment of mania

T2 - An update on new medications

AU - Gajwani, Prashant

AU - Kemp, David E.

AU - Muzina, David J.

AU - Xia, Guohua

AU - Gao, Keming

AU - Calabrese, Joseph R.

PY - 2006/12

Y1 - 2006/12

N2 - Acute mania is frequently a medical emergency requiring hospitalization for behavioral control, rapid resolution of irritability, agitation, de-escalation of mood, and decreasing of risk-taking behavior. Lithium efficacy in the management of acute mania was reported in 1949 and approved by the US Food and Drug Administration (FDA) in 1970. Chlorpromazine, from the class of typical antipsychotics, was approved for treatment of bipolar disorder in 1973. Typical antipsychotics were frequently used alone and as adjunct for the treatment of bipolar mania for the next 2 decades. Divalproex was approved by the FDA for the treatment of acute mania in 1994. Since the approval of olanzapine in 2000, all five atypical antipsychotics, namely risperidone (2003), quetiapine (2004), ziprasidone (2004), and aripiprazole (2004), have been approved by the FDA for the management of acute mania. Clozapine is the only atypical antipsychotic not FDA approved for any phase of bipolar disorder. This article will systematically review some of the major studies published, randomized controlled monotherapy, and adjunct therapy trials involving five atypical antipsychotics and newer anticonvulsants for the treatment of acute bipolar mania.

AB - Acute mania is frequently a medical emergency requiring hospitalization for behavioral control, rapid resolution of irritability, agitation, de-escalation of mood, and decreasing of risk-taking behavior. Lithium efficacy in the management of acute mania was reported in 1949 and approved by the US Food and Drug Administration (FDA) in 1970. Chlorpromazine, from the class of typical antipsychotics, was approved for treatment of bipolar disorder in 1973. Typical antipsychotics were frequently used alone and as adjunct for the treatment of bipolar mania for the next 2 decades. Divalproex was approved by the FDA for the treatment of acute mania in 1994. Since the approval of olanzapine in 2000, all five atypical antipsychotics, namely risperidone (2003), quetiapine (2004), ziprasidone (2004), and aripiprazole (2004), have been approved by the FDA for the management of acute mania. Clozapine is the only atypical antipsychotic not FDA approved for any phase of bipolar disorder. This article will systematically review some of the major studies published, randomized controlled monotherapy, and adjunct therapy trials involving five atypical antipsychotics and newer anticonvulsants for the treatment of acute bipolar mania.

UR - http://www.scopus.com/inward/record.url?scp=33845907401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845907401&partnerID=8YFLogxK

U2 - 10.1007/s11920-006-0058-3

DO - 10.1007/s11920-006-0058-3

M3 - Article

VL - 8

SP - 504

EP - 509

JO - Current Psychiatry Reports

JF - Current Psychiatry Reports

SN - 1523-3812

IS - 6

ER -